



Sotyktu in the UAE

The MoHAP named-patient coordination pathway — indicative 2026

IMMUNOLOGY · MODERATE-TO-SEVERE PLAQUE PSORIASIS

The clinical situation

Sotyktu (deucravacitinib) is an oral, once-daily allosteric TYK2 inhibitor FDA-approved for moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy. Manufactured by Bristol Myers Squibb. Dosing is 6 mg once daily per labeling. Pre-treatment workup covers TB, hepatitis B/C, LFTs, CBC, and vaccination status. Sotyktu has a differentiated label vs the JAK-class boxed warning; your dermatologist confirms indication and monitoring cadence per FDA labeling.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your dermatologist documents psoriasis severity (BSA, PASI, IGA), prior systemic therapies, and Sotyktu rationale.
- 2 Baseline screening.** TB, viral hepatitis, LFTs, CBC, triglycerides, and vaccination status are completed and documented per FDA labeling.
- 3 MoHAP named-patient application.** Physician or hospital pharmacy files clinical rationale, patient reference, strength, quantity, and chain-of-custody plan; DHA or DoH approvals align where applicable.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner with tamper-evident international shipment.
- 5 Arrival & first dose.** Dispensing pharmacy releases product against the prescription; your dermatologist initiates therapy with ongoing monitoring.

Indicative economics

Reference US cash-pay range: USD 6,500–7,500 per 30-tablet month supply of Sotyktu 6 mg (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

7–14 days from a complete MoHAP application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody from Bristol Myers Squibb authorised distribution.

Documentation. Physician kit tailored to MoHAP / DHA / DoH review. **Logistics.** Tamper-evident, internationally tracked shipment. **Concierge case lead.** Named point of contact for family and physician through the case arc. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Sotyktu × UAE first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/sotyktu-uae.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team